| (Values in U.S. Thousands) | May, 2025 | May, 2024 | May, 2023 | May, 2022 | May, 2021 |
| Sales | 48,870 | 58,590 | 62,660 | 66,150 | 57,680 |
| Sales Growth | -16.59% | -6.50% | -5.28% | +14.68% | +24.42% |
| Net Income | -1,050 | 480 | 840 | 5,260 | 6,330 |
| Net Income Growth | -318.75% | -42.86% | -84.03% | -16.90% | +49.65% |
Bioqual Inc (BIOQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BIOQUAL, Inc., formerly Diagnon Corporation, develops, produces and sells diagnostic test kits incorporating monoclonal antibodies to diagnose certain anemias, infections, and parasitic diseases.
Fiscal Year End Date: 05/31